Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Visual Stimulation Through Video Therapy to Enhance Lower Limb Motor Recovery After Stroke (SI-VI-MI)

10. juli 2026 oppdatert av: Arnauld GARCIN, Centre Hospitalier Universitaire de Saint Etienne

Use of Intensive Visual Stimulation Through Video Therapy to Enhance Lower Limb Motor Recovery After Stroke (SIVIMI). A Single-Center Pilot Study Using a Single-Case Experimental Design (SCED)

This pilot study evaluates video therapy for lower limb motor recovery after stroke, an approach remains insufficiently documented.

This single-center pilot study uses a Single-Case Experimental Design (SCED) to evaluate the effects of intensive video therapy combined with conventional rehabilitation in patients with subacute or chronic post-stroke hemiparesis. Twelve participants will be included and allocated to different baseline durations according to a multiple-baseline SCED design.

The primary outcome is functional mobility, assessed using the Timed Up and Go (TUG) test, measured repeatedly throughout baseline, intervention, and follow-up phases.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

Stroke frequently results in persistent lower limb motor impairment affecting gait and functional mobility (1-2). While video-based therapies have shown proof of concept for upper limb rehabilitation after stroke, their effectiveness for lower limb motor recovery remains insufficiently documented (3-5).

This study is a single-center pilot trial using a Single-Case Experimental Design (SCED) with multiple baseline durations, chosen to account for the high interindividual variability observed in subacute and chronic post-stroke patients undergoing rehabilitation (6). This design allows each participant to serve as their own control through repeated measurements over time (6).

Participants are included between 1 month and 1 year post-stroke while receiving inpatient or outpatient rehabilitation in a Physical Medicine and Rehabilitation department. All participants initially undergo a control phase combining standardized rehabilitation with sham video therapy (placebo condition). The duration of this baseline phase is randomized (1, 2, or 3 weeks) across participants.

The experimental phase consists of 5 weeks of intensive video therapy added to usual care, with five sessions per week. A post-intervention sham phase is followed by a follow-up period lasting up to 21 weeks post-intervention, with repeated assessments conducted at weeks 13, 17, and 21 to evaluate maintenance of treatment effects.

The primary objective is to evaluate changes in functional mobility, assessed using repeated measurements of the Timed Up and Go test. Secondary objectives include evaluation of gait endurance, motor impairment, muscle tone, balance, and quality of life

.

Studietype

Intervensjonell

Registrering (Antatt)

12

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Saint-Etienne, Frankrike, 42100
        • Rekruttering
        • Service de Médecine Physique et réadaptation
        • Underetterforsker:
          • Hugo BESSAGUET, MD
        • Underetterforsker:
          • Julia TOULY, MD
        • Ta kontakt med:
        • Underetterforsker:
          • Pascal GIRAUX, MD, PhD
        • Hovedetterforsker:
          • Etienne OJARDIAS, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • - First or recurrent hemispheric ischemic or hemorrhagic stroke in the subacute or chronic phase (from 1 month to 1 year post-stroke).
  • Currently receiving rehabilitation care in a Physical Medicine and Rehabilitation (PM&R) department
  • Able to walk 3 meters back and forth, with or without an assistive device.
  • Provided informed consent, signed jointly with the investigator.

Exclusion Criteria:

  • - Severe hemispatial neglect.
  • Severe spasticity impairing proper positioning (Modified Ashworth Scale > 3).
  • Severe general disabling medical conditions.
  • Associated cerebellar syndrome.
  • Major comprehension disorders, psychiatric illness, or cognitive impairments that could interfere with study participation.
  • Participants under full legal guardianship (tutorship).
  • Pregnant or breastfeeding women.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Sequence 1
1 week of sham videotherapy , 5 weeks of intervention (active videotherapy) , 2 weeks of sham videotherapy.
During active videotherapy sessions, the image inversion program is activated, superimposing movements of the non-paretic limb onto the paretic limb, which is hidden behind the screen. Participants are instructed to imagine and attempt to reproduce the observed movements using their paretic limb. Each participant completes 25 sessions over 5 weeks (5 sessions per week).
During sham videotherapy sessions, participants are seated facing the IVS4 screen without activation of the image inversion program. Participants perform lower limb movements while directly viewing their paretic limb in real time on the screen, corresponding to an action observation condition without visual illusion.
Eksperimentell: Sequence 2
2 weeks of sham videotherapy , 5 weeks of intervention (active videotherapy) , 1 weeks of sham videotherapy.
During active videotherapy sessions, the image inversion program is activated, superimposing movements of the non-paretic limb onto the paretic limb, which is hidden behind the screen. Participants are instructed to imagine and attempt to reproduce the observed movements using their paretic limb. Each participant completes 25 sessions over 5 weeks (5 sessions per week).
During sham videotherapy sessions, participants are seated facing the IVS4 screen without activation of the image inversion program. Participants perform lower limb movements while directly viewing their paretic limb in real time on the screen, corresponding to an action observation condition without visual illusion.
Eksperimentell: Sequence 3
3 weeks of sham videotherapy and 5 weeks of intervention (active videotherapy) ,
During active videotherapy sessions, the image inversion program is activated, superimposing movements of the non-paretic limb onto the paretic limb, which is hidden behind the screen. Participants are instructed to imagine and attempt to reproduce the observed movements using their paretic limb. Each participant completes 25 sessions over 5 weeks (5 sessions per week).
During sham videotherapy sessions, participants are seated facing the IVS4 screen without activation of the image inversion program. Participants perform lower limb movements while directly viewing their paretic limb in real time on the screen, corresponding to an action observation condition without visual illusion.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
1. Timed Up and Go Test (TUG)
Tidsramme: 5-week
Time required to stand up from a chair, walk 3 meters, return, and sit down (in seconds)
5-week

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
2. 2-Minute Walk Test (2MWT)
Tidsramme: Weeks 1, 2, 3, 8, 13, 17, and 21
Walking endurance assessed by the distance walked in 2 minutes (in meters).
Weeks 1, 2, 3, 8, 13, 17, and 21
3. Fugl-Meyer Assessment - Lower Limb Section
Tidsramme: Weeks 1, 2, 3, 8, 13, 17, and 21
Motor function of the hemiplegic lower limb, assessed with the Fugl-Meyer scale (score from 0 to 34)
Weeks 1, 2, 3, 8, 13, 17, and 21
4. Muscle Strength - Foot Dorsiflexors and extensors
Tidsramme: Weeks 1, 2, 3, 8, 13, 17, and 21
Muscle strength of the foot dorsiflexors and extensors, measured in Newtons using a handheld dynamometer
Weeks 1, 2, 3, 8, 13, 17, and 21
5. Muscle Tone - Modified Ashworth Scale (MAS)
Tidsramme: Weeks 1, 2, 3, 8, 13, 17, and 21
Spasticity assessment of dorsiflexors and extensors of the foot using the Modified Ashworth Scale (score 0-5).
Weeks 1, 2, 3, 8, 13, 17, and 21
6. Muscle Tone - Modified Tardieu Scale
Tidsramme: Weeks 1, 2, 3, 8, 13, 17, and 21
Spasticity assessment of dorsiflexors and extensors of the foot using the Modified Tardieu Scale (score 0-5).
Weeks 1, 2, 3, 8, 13, 17, and 21
7. Postural Balance - PASS (Postural Assessment Scale for Stroke Patients)
Tidsramme: Weeks 1, 2, 3, 8, 13, 17, and 21
Balance ability assessed using the PASS scale (score 0-36).
Weeks 1, 2, 3, 8, 13, 17, and 21
8. Quality of Life - Stroke Specific Quality of Life Scale (SS-QOL)
Tidsramme: Weeks 1, 2, 3, 8, 13, 17, and 21
Quality of life assessed with the SS-QOL scale (score range: 49-245).
Weeks 1, 2, 3, 8, 13, 17, and 21

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Etienne OJARDIAS, Dr, Centre Hospitalier Universitaire de Saint Etienne

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. juli 2026

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

30. juni 2028

Datoer for studieregistrering

Først innsendt

21. januar 2026

Først innsendt som oppfylte QC-kriteriene

1. juni 2026

Først lagt ut (Faktiske)

5. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 25CH169
  • 2025-A02102-47 (Annen identifikator: ANSM)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

This study has only 1 center

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere